Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)

被引：2

作者：

Lancet, Jeffrey E. ^{[1
]}

Komrokji, Rami S. ^{[1
]}

Sweet, Kendra L. ^{[1
]}

Duong, Vu H. ^{[2
]}

McGraw, Kathy L. ^{[1
]}

Zhang, Ling ^{[3
]}

Nardelli, Lisa Ann ^{[1
]}

Ma, Zhenjun ^{[4
]}

Reich, Richard R. ^{[5
]}

Padron, Eric ^{[1
,6
]}

List, Alan F. ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[2] Univ Maryland Sch Med, Dept Med, Baltimore, MD USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Hematopathol & Lab Med, Tampa, FL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist & Bioinformat, Tampa, FL USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist & Bioinformat, Tampa, FL USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.3174.3174

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3174

引用

页数：5

共 50 条

[41] Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Oliva, Esther N.
Alati, Caterina
Santini, Valeria
Poloni, Antonella
Molteni, Alfredo
Niscola, Pasquale
Salvi, Flavia
Sanpaolo, Grazia
Balleari, Enrico
Germing, Ulrich
Fenaux, Pierre
Stamatoullas, Aspasia
Palumbo, Giuseppe A.
Salutari, Prassede
Impera, Stefana
Avanzini, Paolo
Cortelezzi, Agostino
Liberati, Anna Marina
Carluccio, Paola
Buccisano, Francesco
Voso, Maria Teresa
Mancini, Stefano
Kulasekararaj, Austin
Morabito, Fortunato
Bocchia, Monica
Cufari, Patrizia
Spiriti, Maria Antonietta Aloe
Santacaterina, Irene
D'Errigo, Maria Grazia
Bova, Irene
Zini, Gina
Latagliata, Roberto
LANCET HAEMATOLOGY, 2017, 4 (03): : E127 - E136
[42] Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
Schweizer, Michael Thomas
Penkov, Konstantin
Choudhury, Atish Dipankar
Calvo, Emiliano
Frank, Richard C.
Liu, Li
Mittapalli, Rajendar K.
Tougias, Jessica
Andreu-Vieyra, Claudia
Bowler, Timothy Geoffrey
Soman, Neelesh
Garmezy, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM
Vey, Norbert
BLOOD, 2018, 132
[44] Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia
Zeidan, Amer M.
Smith, B. Douglas
Carraway, Hetty E.
Gojo, Ivana
Sakoian, Sarah
Gore, Steven D.
DeZern, Amy E.
BLOOD, 2015, 126 (23)
[45] Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial
Garcia-Manero, Guillermo
Yee, Karen W. L.
Hernandez, Francisca
Della Porta, Matteo Giovanni
Paolini, Stefania
Ahn, Seo-Yeon
Santini, Valeria
Fenaux, Pierre
Suzuki, Takahiro
Sekeres, Mikkael A.
He, Jun
Li, Jerry
Barkalifa, Ronit
Vigil, Carlos E.
Prebet, Thomas
de Menezes, Daniel Lopes
Burnett, Joseph
Komrokji, Rami S.
Giagounidis, Aristoteles
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
Taylor, Justin
Mi, Xiaoli
Penson, Alexander, V
Paffenholz, Stella, V
Alvarez, Kelsey
Sigler, Allison
Chung, Stephen S.
Rampal, Raajit K.
Park, Jae H.
Stein, Eytan M.
Tallman, Martin S.
Sen, Filiz
Gonen, Mithat
Abdel-Wahab, Omar
Klimek, Virginia M.
LANCET HAEMATOLOGY, 2020, 7 (08): : E566 - E574
[47] Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Anwar, Asma
Halpern, Anna B.
Othus, Megan
Scott, Bart L.
Hendrie, Paul C.
Becker, Pamela S.
Perdue, Andrea M.
Smith, Heather A.
Chen, Tara L.
Buckley, Sarah A.
Orlowski, Kaysey F.
Powell, Morgan A.
Estey, Elihu H.
Walter, Roland B.
BLOOD, 2015, 126 (23)
[48] A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)
Garcia-Manero, Guillermo
Griffiths, Elizabeth A.
Roboz, Gail J.
Busque, Lambert
Wells, Richard A.
Odenike, Olatoyosi
Steensma, David P.
Yee, Karen W. L.
Faderl, Stefan
Amrein, Philip C.
Michaelis, Laura C.
Kantarjian, Hagop M.
Oganesian, Aram
Lowder, James N.
Azab, Mohammad
Savona, Michael R.
BLOOD, 2017, 130
[49] TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Forman, Seth B.
Pariser, David M.
Poulin, Yves
Vincent, Michael S.
Gilbert, Steven A.
Kieras, Elizabeth M.
Qiu, Ruolun
Yu, Dahong
Papacharalambous, Jocelyne
Tehlirian, Christopher
Peeva, Elena
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (12) : 2359 - +
[50] Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial (vol 109, pg 3209, 2018)
Morita, Yasuyoshi
Maeda, Yasuhiro
Yamaguchi, Terufumi
Urase, Fumiaki
Kawata, Shuhei
Hanamoto, Hitoshi
Tsubaki, Kazuo
Ishikawa, Jun
Shibayama, Hirohiko
Matsumura, Itaru
Matsuda, Mitsuhiro
CANCER SCIENCE, 2020, 111 (09) : 3402 - 3402

← 1 2 3 4 5 →